At the forefront of healthcare evolution, this case study explores how Fiocruz, backed by the
expertise of Caring Cross, is spearheading the local manufacturing of CAR-T cell therapies in
Brazil.
From revolutionizing access to advanced medicinal cures to redefining the landscape of
oncology, infectious, and genetic disease treatments in Latin America, this partnership sets a
new standard for affordable healthcare solutions.
Join us as we unveil the pivotal steps taken to bring life-saving therapies within reach of those
who need them most.
Press Release
Fiocruz and Caring Cross Announce Collaboration Agreement to Enable Access to Affordable CAR-T Therapy in Brazil and Latin America
MAR 26, 2024
Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government’s Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection.
Under the terms of the agreement, Caring Cross will provide technology, materials, and training to the Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz) for the manufacture of CAR-T cell therapies and lentiviral vectors aimed for clinical development and approval.
The initial phase of the program will focus on CAR-T cell therapies for leukemia and lymphoma, improved versions of products that are successfully treating patients in selected countries. The collaboration will also advance a therapeutic product for HIV, currently in U.S. clinical trials, designed for the treatment and potential cure of HIV infection, with the expectation of new co-development projects for other diseases.
